The findings and conclusions in this short article are these of the

The findings and conclusions in this article are those from the authors and do not necessarily represent the views in the Centers for Illness Control and Prevention Author Contributions Conceived and developed the experiments: RMS JRH ED NM-H. Performed the experiments: RMS AM-J MT TS JRH NM-H. Analyzed the data: RMS JRH. Contributed reagents/materials/analysis tools: MT ED NM-H. Wrote the paper: RMS JRH. Revision: JRH RMS. References 1. Casadevall A, Great JR, editors Cryptococcus neoformans. Washington, DC: ASM Press. 542 p. 2. Great JR, Casadevall A The History of Cryptococcus and Cryptococcosis. In: Heitman J, Kozel TR, Kwon-Chung J, Fantastic J, Casadevall A, editors. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press. 1726. 3. Heitman J, Kozel TR, Kwon-Chung J, Fantastic J, Casadevall A, editors Cryptococcus: from pathogen to model yeast. Washington, DC: ASM Press. 4. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. A comparison of amphotericin B alone and combined with flucytosine inside the treatment of cryptoccal meningitis. N Engl J Med 301: 126131. five. Butler WT, Alling DW, Spickard A, Utz JP Diagnostic and Prognostic Value of Clinical and Laboratory Findings in Cryptococcal Meningitis, a Followup Study of Forty Patients. N Engl J Med 270: 5967. 6. Committee UKCHCSS, Garvey L, Winston A, Walsh J, Post F, et al. HIV-associated central nervous method illnesses inside the recent mixture antiretroviral therapy era. Eur J Neurol 18: 527534. 7. Asselman V, Thienemann F, Pepper DJ, Boulle A, Wilkinson RJ, et al. 23148522 Central nervous technique issues after starting antiretroviral therapy in South Africa. AIDS 24: 28712876. 8. Wadhwa A, Kaur R, Bhalla P Profile of central nervous technique illness in HIV/AIDS sufferers with special reference to cryptococcal infections. Neurologist 14: 247251. 9. Kwon-Chung KJ, Bennett JE Epidemiologic differences amongst the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123130. ten. Kwon-Chung KJ, Bennett JE High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A 257: 213218. 11. Speed B, Dunt D Clinical and host variations between infections together with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21: 2834; discussion 3526. 12. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, et al. Cryptococcal meningitis major to blindness in previously wholesome Melanesian adults in Papua New Guinea. Q J Med 87: 343349. 13. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, et al. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189195. 14. Byrnes EJ, 3rd, Li W, Lewit Y, Best JR, Carter DA, et al. Very first reported case of Cryptococcus gattii within the Southeastern USA: implications for travelassociated acquisition of an emerging pathogen. PLoS A single 4: e5851. 15. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, CastanonOlivares LR, MedChemExpress BMS 5 Angeles-Morales V, et al. Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. Initially observations. Mycopathologia 134: 6164. 16. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 4250. 17. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, et al. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical JWH-133 fungus.The findings and conclusions in this report are those of your authors and do not necessarily represent the views in the Centers for Disease Handle and Prevention Author Contributions Conceived and made the experiments: RMS JRH ED NM-H. Performed the experiments: RMS AM-J MT TS JRH NM-H. Analyzed the information: RMS JRH. Contributed reagents/materials/analysis tools: MT ED NM-H. Wrote the paper: RMS JRH. Revision: JRH RMS. References 1. Casadevall A, Fantastic JR, editors Cryptococcus neoformans. Washington, DC: ASM Press. 542 p. 2. Ideal JR, Casadevall A The History of Cryptococcus and Cryptococcosis. In: Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A, editors. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press. 1726. three. Heitman J, Kozel TR, Kwon-Chung J, Great J, Casadevall A, editors Cryptococcus: from pathogen to model yeast. Washington, DC: ASM Press. four. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. A comparison of amphotericin B alone and combined with flucytosine inside the remedy of cryptoccal meningitis. N Engl J Med 301: 126131. 5. Butler WT, Alling DW, Spickard A, Utz JP Diagnostic and Prognostic Value of Clinical and Laboratory Findings in Cryptococcal Meningitis, a Followup Study of Forty Individuals. N Engl J Med 270: 5967. 6. Committee UKCHCSS, Garvey L, Winston A, Walsh J, Post F, et al. HIV-associated central nervous method illnesses inside the current mixture antiretroviral therapy era. Eur J Neurol 18: 527534. 7. Asselman V, Thienemann F, Pepper DJ, Boulle A, Wilkinson RJ, et al. 23148522 Central nervous program disorders right after starting antiretroviral therapy in South Africa. AIDS 24: 28712876. 8. Wadhwa A, Kaur R, Bhalla P Profile of central nervous program illness in HIV/AIDS patients with particular reference to cryptococcal infections. Neurologist 14: 247251. 9. Kwon-Chung KJ, Bennett JE Epidemiologic variations between the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123130. ten. Kwon-Chung KJ, Bennett JE Higher prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A 257: 213218. 11. Speed B, Dunt D Clinical and host variations in between infections using the two varieties of Cryptococcus neoformans. Clin Infect Dis 21: 2834; discussion 3526. 12. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, et al. Cryptococcal meningitis major to blindness in previously healthy Melanesian adults in Papua New Guinea. Q J Med 87: 343349. 13. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, et al. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189195. 14. Byrnes EJ, 3rd, Li W, Lewit Y, Ideal JR, Carter DA, et al. Initially reported case of Cryptococcus gattii in the Southeastern USA: implications for travelassociated acquisition of an emerging pathogen. PLoS One particular 4: e5851. 15. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, CastanonOlivares LR, Angeles-Morales V, et al. Cryptococcus neoformans var. gattii amongst patients with cryptococcal meningitis in Mexico. 1st observations. Mycopathologia 134: 6164. 16. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection inside the Pacific Northwest, USA. Emerg Infect Dis 13: 4250. 17. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, et al. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus.